Search Results
Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?
Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma
Joseph M. Connors, MD: Optimizing Therapy, Minimizing Toxicity in Hodgkin Lymphoma
Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma
Addition of Targeted Drug Reduces Risk of First-Line Treatment Failure in Advanced Hodgkin Lymphoma
Debate: Best upfront approach for Advanced Stage Hodgkin Lymphoma? - A (brentuximab vedotin) VD
Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphoma
Debate: Brentuximab vedotin as upfront therapy for advanced Hodgkin lymphoma? - Yes
ASH 2017 - Joseph M Connors Interview
Brentuximab Vedotin Plus AVD: Limiting Toxicity in Limited-Stage Hodgkin Lymphoma
A Study of Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma
